ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,496, issued on Dec. 30, was assigned to Shanghai Minwei Biotechnology Co. LTD (Shanghai).
"GLP-1/glucagon dual agonist fusion protein" was invented by Weiyue Han (Guangdong, China).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a GLP-1/glucagon dual agonist and an application thereof. Specifically, the present invention provides a GLP-1 mutation protein, and the GLP-1 mutation protein simultaneously has the activity of binding and activating a class B G protein-coupled receptor GLP-1R, and the activity of a glucagon receptor. By applying a compound, calorie consumption can be increased by means of glucagon activity so a...